It is notable that the combination of PODXL with ITGB1 and the combination of BCL7B with ITGB1 accurately predicted the postoperative outcomes of pancreatic cancer patients with or without adjuvant therapies. Here, BCL7B is linked to familial pancreatic carcinoma.